A new modelling study from RespiCompass, the ECDC Respiratory Diseases Scenario Modelling Hub, indicates that influenza and COVID-19 vaccination programmes markedly reduced hospitalisations among older adults across Europe in the 2024/25 season.

In partnership with ESWI, the Coalition for Life Course Immunisation has released a new policy brief highlighting the urgent need for a more coordinated, life-course approach to respiratory virus prevention across the EU.

Check out this Satellite Symposium organised by the ESWI IDC and supported by IFPMA and Sanofi from ESWI2026.

Annual influenza epidemics in the United States cause hundreds of thousands of hospitalizations.

Global influenza and COVID-19 activity stayed low in late October 2025. COVID-19 was more common in northern regions, while influenza spread mainly in tropical areas.

In self‐controlled case series studies, laboratory‐confirmed influenza infection was associated with an elevated risk of acute myocardial infarction and stroke during the first 1 month.

It’s difficult to predict just how severe the influenza season will be each year, but public health experts say it could be harsh in Europe due to lagging vaccination rates and early signals from far-flung countries such as Japan and Australia.

Two large-scale trials comparing high-dose inactivated influenza vaccine (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) against hospitalisation outcomes have been conducted in Denmark and Spain.